Cingles Info

InterMune Promotes Dr. Brian Murphy to Vice President of Marketing And
Commercial Strategy, Hepatology
Thursday November 21, 4:05 pm ET
BRISBANE, Calif., Nov. 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq:
ITMN - News) announced today that it has promoted Brian Murphy, M.D., to the
position of Vice President of Marketing and Commercial Strategy, Hepatology. In
this role, Dr. Murphy will provide strategic direction and management oversight
to the company's hepatology marketing group. His main focus will be to establish
InterMune as a leader in the hepatology marketplace, particularly in the areas
of chronic hepatitis C and hepatic fibrosis. He will report directly to David
Cory, Senior Vice President of Sales and Marketing at InterMune.
"I am pleased and excited to have Dr. Murphy join the Infergen team," said Mr.
Cory. He brings a tremendous clinical and commercial background in hepatology
and experience that will help position InterMune as a leader in the treatment of
HCV."
Dr. Murphy joined InterMune in March 2002 as Director of Clinical Research for
Hepatology. Prior to joining InterMune, he served as U.S. Medical Director for
Interferons at Roche Pharmaceuticals. Previously, he was Director of the
Clinical Strategies Program for the St. Vincent's Catholic Healthcare Network of
New York and a practicing physician with a research focus on clinical
epidemiology. Dr. Murphy is a member of Alpha Omega Alpha National Honor Medical
Society, as well as the New York Academy of Sciences. He has held academic
appointments at the Harvard Medical School and School of Public Health and
lectures at the Columbia University Graduate School of Business.
He earned his M.D. and M.S. in Pharmacology at New York Medical College and
served his residency and chief residency in internal medicine at Tufts-New
England Medical Center and Boston University, respectively. He completed joint
fellowships at Harvard Medical School and Massachusetts General Hospital with a
dual focus in clinical epidemiology and medicine. He received his MPH from the
Harvard School of Public Health and his MBA from Columbia University. Dr. Murphy
serves as a reviewer for a number of medical publications, including the Annals
of Internal Medicine and the New England Journal of Medicine.
About InterMune
InterMune is a commercially driven biopharmaceutical company focused on the
marketing, development and applied research of life-saving therapies for
pulmonary disease, infectious disease and cancer. For additional information
about InterMune, please visit www.intermune.com.